Corcept Therapeutics (CORT) is back on investors radar after fresh analyst commentary spotlighted its pipeline, particularly relacorilant, ahead of a key PDUFA decision for Cushing’s syndrome later ...

While sales of its flagship product, Korlym, grew about 14% year-over-year to $207.6 million, Corcept revised its full-year 2025 revenue guidance downward to a range of $800–850 million, from a prior ...

Corcept Therapeutics Incorporated (NASDAQ:CORT) is one of the best biotech stocks to buy according to Wall Street analysts.

Additionally, NDC-011, a novel drug combination developed through DR.NOAH's AI-based drug discovery platform, received Orphan Drug Designation (ODD) from the U.S. FDA in 2023 and IND approval for a ...

According to DelveInsight's analysis, the acute on chronic liver failure market is anticipated to increase during the forecast period (2025--2034), owing to the launch of emerging therapies such as ...

AppFolio Inc. (NASDAQ: APPF) is among the best stocks you’ll wish you bought sooner. As of December 1, the company is a ...

Corcept (CORT) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

On December 4, a recent SEC filing unveiled that William Guyer, Chief Development Officer at Corcept Therapeutics (NASDAQ: CORT) made an insider sell.

Corcept Therapeutics CORT has been making meaningful progress with its sole-marketed drug, Korlym (mifepristone), which is ...

Corcept Therapeutics Incorporated (NASDAQ:CORT) is a must-buy non-tech stock to invest in. On November 17, analysts at Wolfe ...

Fintel reports that on November 25, 2025, HC Wainwright & Co. reiterated coverage of Corcept Therapeutics (NasdaqCM:CORT) with a Buy recommendation. Analyst Price Forecast Suggests 77.49% Upside As of ...